

1 **Redox imbalance and oxidative DNA damage during isoniazid treatment:**

2 **A clinical and translational pharmacokinetic study**

3  
4 Isaac Zentner<sup>1</sup>, Hyun-moon Back<sup>2</sup>, Leonid Kagan<sup>2</sup>, Selvakumar Subbian<sup>1</sup>, Jyothi Nagajyothi<sup>1</sup>,  
5 Shashikant Srivastava<sup>3</sup>, Jotam Pasipanodya<sup>3</sup>, Tawanda Gumbo<sup>3</sup>, Gregory P. Bisson<sup>4</sup>, Christopher  
6 Vinnard<sup>1</sup>

7 <sup>1</sup>Public Health Research Institute, New Jersey Medical School, Newark, NJ, USA

8 <sup>2</sup>Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA

9 <sup>3</sup>Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX, USA

10 <sup>4</sup>University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

11  
12 Corresponding author:

13 Christopher Vinnard, MD MPH MSCE

14 Public Health Research Institute

15 225 Warren Street

16 Newark, NJ 07103

17 christopher.vinnard@njms.rutgers.edu

18  
19 Abstract word count: 252

20 Word count: 4557

21 Number of tables: 3

22 Number of figures: 5

23 Number of supplemental figures: 1

24 Number of supplemental tables: 3

25 Number of references: 36

26 **ABSTRACT**

27 **Background:** The potential for hepatotoxicity during isoniazid-based tuberculosis (TB) treatment  
28 presents a major challenge for TB control programs worldwide. We sought to determine whether  
29 pharmacokinetic exposures of isoniazid and its metabolites were related to cellular oxidation/reduction  
30 status and downstream markers of oxidative DNA damage.

31 **Methods:** We performed intensive pharmacokinetic sampling among isoniazid-treated patients to  
32 determine the relative plasma exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine.  
33 Physiologically-based pharmacokinetic modeling was used to estimate liver tissue exposures during a  
34 24-hour dosing interval for each compound. We experimentally treated HepG2 cells with isoniazid and  
35 metabolites at equimolar concentrations corresponding to these exposures for 7, 14, and 28 day  
36 periods, and performed assays related to redox imbalance and oxidative DNA damage at each  
37 timepoint. We related a urine marker of oxidative DNA damage to serum isoniazid pharmacokinetic  
38 exposures and pharmacogenetics in a clinical study.

39 **Results:** Among isoniazid-treated patients, serum concentrations of hydrazine and isoniazid  
40 concentrations were highly correlated. At equimolar concentrations that approximated hepatic tissue  
41 exposures during a 24-hour dosing interval, hydrazine demonstrated the highest levels of redox  
42 imbalance, mitochondrial injury, and oxidative DNA damage over a 28-day treatment period. In a  
43 clinical validation study of isoniazid-treated TB patients, peak isoniazid serum concentrations were  
44 positively associated with a urine biomarker of oxidative DNA damage.

45 **Conclusions:** Isoniazid and its metabolites share the potential for oxidative cellular damage, with the  
46 greatest effects observed for hydrazine. Future studies should investigate the clinical consequences of  
47 oxidative stress with regards to clinical episodes of drug induced liver injury during isoniazid treatment.

48

## 49 **BACKGROUND**

50 The potential for isoniazid hepatotoxicity during tuberculosis (TB) treatment remains a major challenge  
51 for TB control efforts worldwide. In the United States, isoniazid is the second leading cause of drug-  
52 induced liver injury, with evidence of under-reporting<sup>1</sup>. Aside from the direct effects of patient injury, the  
53 potential for hepatotoxicity during isoniazid treatment places additional burdens on TB control  
54 programs<sup>2</sup>, including laboratory monitoring and treatment interruptions, and hampers drug development  
55 efforts<sup>3</sup>. The risk of isoniazid-related hepatotoxicity is further increased in the setting of co-infection with  
56 human immunodeficiency virus (HIV)<sup>4</sup>.

57

58 A central challenge to understanding isoniazid hepatotoxicity has been its idiosyncratic nature, lacking  
59 a clear relationship with dose size<sup>5</sup>. Damage mediated by reactive oxygen species (ROS), as a  
60 consequence of imbalance between cellular oxidation and reduction<sup>6</sup>, is a key determinant of drug  
61 hepatotoxicity<sup>7,8</sup>. The imbalance between oxidation and reduction processes overwhelms cellular  
62 stores of glutathione, which provides an intracellular sink for ROS directed by the glutathione-s-  
63 transferase (GST) family of proteins<sup>9</sup>. With its high cellular density of mitochondria, the liver is  
64 particularly vulnerable to injury from ROS byproducts, leading to free radical-induced modifications of  
65 host proteins, DNA, and lipids<sup>10</sup>.

66

67 While there is abundant evidence that isoniazid and its metabolites cause redox imbalance in  
68 mammalian cells<sup>5,11,12</sup>, clinical studies have not yet linked isoniazid parent-metabolite pharmacokinetic  
69 exposures with markers of oxidative stress. Hydrazine, an isoniazid metabolite that damages the  
70 electron transport chain in mitochondria, has been proposed as a primary driver of isoniazid  
71 hepatotoxicity, yet pre-clinical studies have evaluated concentrations higher than those achieved in  
72 patients during isoniazid treatment. Establishing the link, if any, between markers of oxidative stress  
73 and hepatotoxicity during isoniazid treatment could lead to alternate approaches to monitoring during  
74 treatment, personalization of isoniazid dosing, or the development of ameliorating therapeutic strategies

75 for toxicity prevention<sup>13</sup>. Here, we hypothesized that long-term exposures to isoniazid and its  
76 metabolites were related to markers of redox imbalance in hepatocytes, and that hydrazine exposures  
77 would drive redox imbalance and oxidative damage in the liver.

78

## 79 **METHODS**

80 Clinical pharmacokinetic study to determine relative plasma exposures of isoniazid, acetylisoniazid,  
81 hydrazine, and acetylhydrazine

82 We performed intensive pharmacokinetic sampling for drug and metabolite concentrations in 10 TB  
83 patients (4 latent infection patients and 6 active TB patients) treated with isoniazid, in order to identify  
84 the relevant metabolite concentrations for subsequent pre-clinical experiments. After an overnight fast,  
85 patients were dosed with oral isoniazid (300 mg). A pre-dose blood draw was performed, with additional  
86 blood draws at 1, 2, 4, 6, and 8 hours after dosing. Following centrifugation, plasma samples were  
87 stored at -80C until shipment to Alturas Analytics (Moscow, ID) for analysis. At each timepoint, we  
88 measured plasma concentrations of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine (Figure  
89 1). Noncompartmental pharmacokinetic analysis was performed to determine area under the  
90 concentration-versus-time curve (AUC), extrapolated over a 24-hour dosing interval according to the  
91 slope defined in the elimination phase.

92

93 Physiologically-based pharmacokinetic model of liver tissue exposures of isoniazid and its metabolites

94 To predict the hepatic tissue exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine  
95 during isoniazid treatment, the whole-body physiologically based pharmacokinetic model with advanced  
96 compartmental and transit model in GastroPlus (Ver 9.7) was used (Supplementary Figure 1). All  
97 physicochemical properties for those substances were predicted based on chemical structure from a  
98 built-in predictor in GastroPlus. Population-dependent physiological parameters, including tissue  
99 volumes and perfusion rate in humans, were obtained using the Population Estimates for Age-Related  
100 Physiology module in GastroPlus (Supplementary Table 1). After simulating time-versus-concentration

101 profiles of substances in liver and plasma, noncompartmental pharmacokinetic analysis was performed  
102 to calculate the AUC<sub>0-24</sub> ratio between liver and plasma. This ratio was used to predict liver tissue  
103 exposures to isoniazid and metabolites, during a 24-hour dosing interval, based on the observed  
104 plasma exposures in the clinical study.

105

#### 106 *In vitro* pharmacologic exposures of hepatocytes to isoniazid and its metabolites

107 The human liver carcinoma cell line, HepG2, is highly differentiated and is often used to screen the  
108 cytotoxicity potential of new chemical entities early in drug development<sup>14</sup>. HepG2 cells were cultured in  
109 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100  
110 U/mL penicillin, 100 µg/ml streptomycin and 2mM L-glutamine, unless otherwise stated. Cells were  
111 continuously incubated at 37°C in a humidified 5% CO<sub>2</sub> / 95% air environment and plated in a 12-well  
112 plate at 4x10<sup>5</sup> cells/well, over a duration of 24 hours prior to compound exposure. Compound stocks  
113 dissolved in water were freshly made each exposure day. Cellular supernatant was replaced with 2 mL  
114 of culture media containing 10 µM of compound and left to incubate until 90% confluency was reached.  
115 Cell passages were conducted every 3 days under continual exposure to the designated compound for  
116 the indicated time period. Cellular supernatant was collected at each passage, clarified, aliquoted, and  
117 stored at -80°C for future analysis. Treated cells and supernatants were then examined for markers of  
118 cytotoxicity, mitochondrial toxicity, and oxidative DNA damage as described below.

119

#### 120 *Free thiol availability assay*

121 By serving as targets of ROS, thiols provide the cellular defense system against oxidative stress.  
122 Glutathione is the principal non-protein thiol in most cells, and high intracellular glutathione  
123 concentrations are required to maintain protein thiols in reduced states, which is essential for cellular  
124 functions in metabolism, signaling, and detoxification<sup>15</sup>. Cellular glutathione depletion was quantified in  
125 a free thiol availability assay<sup>16</sup>. Black 96-well polystyrene clear bottom plates were coated with 50  
126 µg/mL of poly-d-lysine for 1 hour at 37°C. Following multiple washes with PBS, HepG2 cells from the

127 long-term low-exposure culture growth, at the indicated times, were plated at  $3.3 \times 10^5$  cells per well and  
128 left to incubated at 37°C for 12 hours maintain compound exposure. ThiolTracker™ Violet dye  
129 (ThermoFisher) was used to asses free thiol availability following the manufacturer's instructions.  
130 Briefly, cells were washed two times with D-PBS +C/M prior to the addition of 20 µM of ThiolTracker.  
131 Following a 30 min incubation at 37°C, cells were washed three times with D-PBS +C/M. Fluorescent  
132 intensity at 404nm<sub>Ex</sub>/526nm<sub>Em</sub> was measured on a Synergy H1 Hybrid Multi-Mode Reader (BioTek).

133

#### 134 *Mitochondrial membrane integrity*

135 To assess mitochondrial membrane integrity, black 96-well polystyrene clear bottom plates were coated  
136 with 50 µg/mL of poly-d-lysine for 1 hour at 37°C. Following multiple washes with PBS, HepG2 cells  
137 from the long-term low-exposure culture growth, at the indicated times, were plated at  $3.3 \times 10^5$  cells per  
138 well and left to incubated at 37°C for 12 hours maintaining compound exposure. Tetramethylrhodamine,  
139 methyl ester (ThermoFisher, Waltham, Massachusetts) was added at 100 nM at 37°C for 30 minutes.  
140 Following three washes with PBS, fluorescent intensity at 488nm<sub>Ex</sub>/570nm<sub>Em</sub> was measured on a  
141 Synergy H1 Hybrid Multi-Mode Reader (BioTek).

142

#### 143 *Cellular and mitochondrial toxicity*

144 Mitochondrial toxicity analysis was assayed using the Mitochondrial ToxGlo Assay (Promega, Madison,  
145 WI) following the manufacturer's instructions. Briefly, cells obtained from the long-term low-exposure  
146 culture growth, at the indicated times, were grown in a 96-well flat clear bottom black polystyrene plate  
147 at  $3.3 \times 10^5$  cells per well in glucose-free (galactose supplemented) culture media. Compound  
148 concentrations (10 µM) were consistently maintained throughout the experiment. Following a 24-hour  
149 incubation with compound, cytotoxicity was evaluated by the addition of a fluoregenic peptide substrate,  
150 bis-AAF-R110, to the cell supernatant for 30 minutes at 37°C. The bis-AAF-R110 substrate penetrates  
151 compromised plasma membranes and is activated via interactions with necrosis-associated proteases.  
152 After the cells were allowed to incubate for 30 minutes at 37°C, fluorescence intensity was measured at

153 485nm<sub>Ex</sub>/525nm<sub>Em</sub>. To evaluate mitochondrial toxicity, the plate was acclimated to room temperature for  
154 5 minutes, at which point the ATP detection reagent was added. Cell lysis mixture was transferred to a  
155 96-well flat solid white bottom plate and luminescence intensity was measured. Assays of fluorescence  
156 and luminescence activity were performed with a Synergy H1 Hybrid Multi-Mode Reader (BioTek,  
157 Winooski, VT).

158

### 159 *Comet chip imaging of cellular DNA damage*

160 Cells treated for 1 week with 10  $\mu$ M of compound were plated onto a CometChip (Trevigen) at  $2 \times 10^5$   
161 cells/mL in a single cell suspension<sup>17</sup>. Cells were incubated on the chip for 60 min at 37°C. The plate  
162 was then gently washed with PBS and coated with 1% low melting agarose. After the agarose was  
163 solidified by cooling at 4°C, the plate was washed with pre-chilled non-activated alkaline lysis buffer  
164 (2.5 M NaCl, 100nM Na<sub>2</sub>EDTA, 10mM Tris, pH 10). The chip was lysed overnight at 4°C by submerging  
165 the chip in the alkaline lysis buffer containing 1% Triton-X. The plate was then washed with PBS and  
166 placed in an electrophoresis chamber filled with pre-chilled alkaline electrophoresis buffer (2mM Na<sub>2</sub>  
167 EDTA, 300 mM NaOH). Following a 40 min incubation at 4°C to allow for alkaline unwinding,  
168 electrophoresis was carried out at 80 volts for 30 min at 4°C. The chip was then neutralized with two  
169 incubations at 4°C in 400 mM Tris, pH 7.5 buffer, and equilibrated in 20 mM Tris, pH 7.4 at 4°C for 20  
170 min. DNA staining was achieved by incubating the chip in 100 mL of 0.2X SYBR Gold overnight at 4°C.  
171 Fluorescent images were acquired on an Evos FL Imaging System (ThermoFisher).

172

### 173 *Immunofluorescence for $\gamma$ -H2Ax*

174 H2Ax is a core histone protein found in the nucleosome, and the phosphorylation of H2Ax is a marker  
175 of DNA damage caused by ROS. Variant histone H2AX ( $\gamma$ -H2AX) is a marker of DNA double-strand  
176 breaks<sup>18</sup>. Exposed cells (1 week with 10  $\mu$ M of compound) were plated in a 12-well cell culture treated  
177 plate at  $1 \times 10^5$  cells/well. Following 24 hours incubation at 37°C in media containing 10  $\mu$ M of  
178 compound, cells were fixed with a cold 1:1 solution of methanol and acetone for 20 min at -20°C. The

179 cells were subsequently washed with PBS and blocked for 2 hours at room temperature with 1 mL of  
180 BlockAid™ Blocking Solution (Thermo Scientific). Each well was stained with a 1:1000 dilution of rabbit  
181 anti-phospho-H2AFX (Millipore Sigma, St. Louis, MO) in PBS overnight at 4°C with gently rocking.  
182 Following multiple washing steps with PBS, cells were incubated with 5 µg/mL of anti-rabbit Alexa Fluor  
183 647-conjugated antibody (ThermoFisher) for 1 hour at room temperature. Cells were subsequently  
184 washed with PBS and stained with 1 µg/mL of Hoechst 33342 (ThermoFisher) for 5 min at room  
185 temperature. Fluorescent images were acquired on an Evos FL Imaging System (ThermoFisher).

186

### 187 *8-Hydroxy-2'-deoxyguanosine (8-OHdG) in cellular supernatant*

188 Determination of 8-OHdG content in cellular supernatant was assed using an in-house competition  
189 ELISA. Clear 96-well plates were coated with 8-Hydroxy-2'-deoxyguanosine (BioVision, Milpitas, CA)  
190 overnight at 4°C. Plates were then washed three times with PBS. Cell supernatant in PBS or standard  
191 8-OHdG standard curve dilutions were added to the appropriate wells. Rabbit anti-8-OHdG (Abcam,  
192 Cambridge, MA) was subsequently added at a 1:2500 final dilution in PBS and the plate was incubated  
193 at room temperature with shaking for 2 hours. Following three washes with PBS, anti-rabbit HRP  
194 antibody was added at a 1:5000 dilution and the plate was incubated at room temperature with shaking  
195 for 1 hour. Immediately following five rapid PBS washes, 3.7mM o-phenylenediamine in 0.05 M  
196 phosphate-citrate buffer containing 0.03% sodium perborate was added and the plate was incubated at  
197 room temperature protected from light for 30 minutes. Absorbance at 405 nm was then measured on a  
198 Synergy H1 Hybrid Multi-Mode Reader (BioTek).

199

### 200 Clinical validation of urine oxidative DNA damage in HIV/TB patients

#### 201 *Study setting and subjects*

202 We conducted a prospective cohort study of isoniazid pharmacokinetics among HIV/TB patients at 22  
203 public clinics and Princess Marina Hospital in Gaborone, Botswana. The study population has been  
204 previously described<sup>19</sup>. Eligibility criteria included citizens of Botswana, HIV infected adults (21 years of



205 age or older) naïve to ART therapy, and newly diagnosed with pulmonary TB initiated on standard first-  
206 line TB regimens at weight-based dosing bands recommended in accordance with WHO guidelines.  
207 The study visit occurred between 5 and 28 days after initiation of first-line TB therapy that included  
208 isoniazid, prior to initiation of ART therapy.

209

### 210 *Data collection*

211 After an overnight fast, the anti-TB drugs were directly administered. Blood samples (10 mL) were  
212 drawn at 0, 0.3, 0.9, 2.2, 4.5, and 8 hours post-dosing, based on optimal sampling theory to estimate  
213 isoniazid pharmacokinetic parameters. Plasma isoniazid concentrations were measured with liquid  
214 chromatography-tandem mass spectrometry (LC-MS/MS) methods as previously described. The peak  
215 plasma concentration ( $C_{max}$ ) was obtained directly from the concentration-versus-time data), model-  
216 predicted isoniazid concentrations were used to estimate the area under the concentration-versus-time  
217 curve during a 24-hour interval ( $AUC_{0-24}$ ). A spot urine sample (approximately 50 mL) was collected 4  
218 hours following anti-TB drug dosing and frozen at -80C until analysis. We measured urinary  
219 concentrations of 8-OHdG, a marker of oxidative DNA damage that is stable in cryopreserved urine  
220 samples, normalized to urine creatinine. The DNA Damage Competitive ELISA kit (ThermoFisher  
221 Scientific) was performed using a 1:4 dilution of urine-to-assay buffer. The manufacturer's instructions  
222 were followed with one modification to the protocol. Antigen binding was performed overnight at 4°C  
223 with shaking in lieu of a 2-hour incubation at room temperature. Each assay was performed in triplicate.  
224 Optical absorption was assessed using a Synergy H1 Hybrid Multimode Reader (BioTek). To obtain  
225 creatinine concentrations for all urine, the Creatinine Urinary Detection Kit (ThermoFisher Scientific)  
226 was performed according to the manufacturer's instructions using a 1:20 dilution of urine-to-deionized  
227 water.

228

### 229 *Pharmacogenetic genotyping for NAT2 and GST family genes*

230 DNA from whole blood samples was used to perform whole exome sequencing as previously  
231 described<sup>19</sup>. Individuals with any combinations of the following NAT-2 alleles: 2\*4, 2\*11, 2\*12 and 2\*13,  
232 were classified rapid acetylators, while those with both combination of these alleles: 2\*5, 2\*6, 2\*7 and  
233 2\*14, were considered slow acetylators, in accordance with existing literature<sup>20</sup>. Patients who  
234 possessed one allele from the former group and another from the later were classified as intermediate  
235 acetylators. Patients whose single-nucleotide polymorphism (SNP) calls were not available in public  
236 databases (<http://nat.mbg.duth.gr/> and <http://NAT-2pred.rit.albany.edu/>) or published literature were  
237 designated as ambiguous. We evaluated allele frequencies in SNPs corresponding to GST family  
238 genes based on previously identified clinical associations with oxidation/reduction status or isoniazid  
239 hepatotoxicity, including *GSTA2*, *GSTP1*, and *GSTM1*<sup>21,22</sup>. Based on a previously published  
240 classification scheme<sup>23</sup>, we categorized *GSTA2* haplotypes according to four SNPs (rs2180314,  
241 rs6577, rs2234951, rs1803682), as shown in Supplementary Table 3.

242

### 243 Statistical analysis

244 Pharmacokinetic analyses were performed in Phoenix 8.0 (Certara USA, Inc., Princeton, NJ), and  
245 physiologically based pharmacokinetic modeling was performed GastroPlus v9.7 (SimulationsPlus,  
246 Redwood City, CA). Multivariate regression modeling was performed in Stata v13 (College Station, TX:  
247 StataCorp LP). Plots were generated in GraphPad Prism version 7.00 for Windows (GraphPad  
248 Software, La Jolla, CA, [www.graphpad.com](http://www.graphpad.com)). Statistical significance was declared for p-values less  
249 than 0.05.

250

## 251 **RESULTS**

### 252 Pharmacokinetic exposures to isoniazid and its metabolites in TB patients

253 We obtained parent-metabolite pharmacokinetic data from 10 isoniazid-treated patients, including 4  
254 patients with latent TB infection and 6 patients with active TB disease. The properties of the HPLC-  
255 MS/MS plasma assays for isoniazid and metabolites are included in Supplementary Table 2. The

256 spaghetti plots of pharmacokinetic profiles are shown in Figure 2 for isoniazid (Figure 2a),  
257 acetylisoniazid (Figure 2b), hydrazine (Figure 2c), and acetylhydrazine (Figure 2d). For isoniazid,  
258 acetylisoniazid, and acetylhydrazine, all concentrations were greater than the lower limit of  
259 quantification, corresponding to 1 ng/mL, 10 ng/mL, and 10 ng/mL for isoniazid, acetylisoniazid, and  
260 acetylhydrazine, respectively. For hydrazine, 6 of 60 concentrations (10%) were below the lower limit of  
261 quantification, corresponding to 2 ng/mL. As expected, plasma  $AUC_{0-24}$  exposures for isoniazid and  
262 hydrazine were highly correlated ( $R^2 = 0.78$ ), consistent with the role of NAT2 enzyme in the  
263 metabolism of each compound (Figure 1).

264

265 The physiologically based pharmacokinetic model of isoniazid and metabolite distribution into tissue is  
266 included in Supplementary Figure 1. Based on this model, we predicted ratios of liver tissue:plasma  
267 exposures for isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine as shown in Table 1. The  
268 model predicted an 18-fold higher liver tissue exposure for hydrazine compared to plasma, but lower  
269 liver tissue exposures for parent compound and the other metabolites compared to plasma. Based on  
270 these model-predicted liver tissue exposures, we selected the concentration of 10  $\mu$ M to study in pre-  
271 clinical toxicodynamic models for all compounds, corresponding to an  $AUC_{0-24}$  of 240  $\mu$ M\*hr. This molar  
272 concentration fell within 1 log-10 for the median exposure to each compound.

273

274 Long-term exposures of HepG2 cells treated at clinically relevant concentrations of isoniazid and  
275 metabolites

276 *Biochemical assays of redox imbalance and mitochondrial injury*

277 There was no appreciable cytotoxicity and of isoniazid or its metabolites (Figure 3a). However, we  
278 observed thiol depletion in treated cells over the 28-day exposure period, demonstrating impaired  
279 cellular capacity to maintain the oxidation-reduction equilibrium, greatest among hydrazine-treated cells  
280 (Figure 3b). TMRM is a cell-permeant dye that accumulates in active mitochondria with intact  
281 membrane potential and is depleted with free radical injury to mitochondrial membrane potential. Figure

282 3c shows that there was TMRM depletion in all treated cells across 28 days of exposure, with the  
283 greatest depletion observed for hydrazine. Furthermore, Figure 3d shows that cellular ATP production  
284 was impaired at 28 days of treatment across all experiments, again with the greatest impairment  
285 observed for hydrazine as compared with the other compounds.

286

### 287 *Microscopic and biochemical assays of oxidative DNA damage*

288 We examined levels of oxidative DNA damage in treated HepG2 cells in several ways. First,  
289 CometChip microscopy demonstrated greater levels of DNA damage in cells treated for 1 week with  
290 hydrazine, acetylhydrazine, and acetylisoniazid, as compared to isoniazid (Figure 4a). Next, we  
291 measured  $\gamma$ -H2AX in treated cells, a variant histone which corresponds to the presence of double-  
292 stranded DNA breaks. Following a 1-week exposure period,  $\gamma$ -H2AX levels were greatest during  
293 treatment with hydrazine, as compared to isoniazid, acetylisoniazid, and acetylhydrazine (Figure 4b).  
294 Finally, we examined cellular supernatant levels of 8-OhDG, a measure of oxidative DNA damage that  
295 is stable in cryopreserved clinical samples<sup>24</sup>. Figure 4c shows that the highest increase in 8-OhDG  
296 levels in cell supernatant was with hydrazine treatment. Given that the 10  $\mu$ M concentration used in  
297 these experiments was less than predicted in liver tissue for hydrazine, but greater than predicted for  
298 isoniazid and non-hydrazine metabolites, these findings collectively supported our hypothesis that  
299 hydrazine is the primary mediator of redox imbalance in hepatocytes.

300

### 301 Oxidative DNA damage among isoniazid-treated TB patients

302 To further test the clinical relevance of these in vitro findings, we collected urine samples obtained in a  
303 previously conducted clinical pharmacokinetic study of HIV/TB patients,<sup>19</sup> to test for 8-OhDG  
304 concentrations, a stable marker of oxidative DNA damage, which has been linked to exposures to  
305 toxins such as cadmium<sup>25</sup>, chromium, and lead<sup>26</sup> in other patient cohorts. Demographic, clinical, and  
306 immunologic characteristics of study participants are shown in Table 2, which shows that none of the  
307 characteristics differed *NAT2* genotype. However, *NAT2* genotype was associated with urine 8-OhDG

308 concentrations, as shown in Figure 5a. In unadjusted analysis, we observed a significant increase in  
309 urine oxidative DNA damage among patients with slow NAT2 genotypes, compared to rapid acetylator  
310 genotypes ( $p=0.04$ ). Next, we examined *GSTA2*, which encodes the dominant GST protein in human  
311 livers, and demonstrates population variability that corresponds to varying levels of hepatic GST  
312 expression<sup>22</sup>. The rs2234951 and rs1803682 variants were not detected in the study cohort, while the  
313 SNPs rs6577 and rs2180314 were in complete linkage disequilibrium. Accordingly, all haplotypes were  
314 either *GSTA2*\*B or \*C under the naming schema proposed by Tetlow *et al*<sup>23</sup> (Supplementary Table 3).  
315 We identified 25 patients with the homozygous *GSTA2*\*B/\*B haplotype (rs6577/rs6577), 12 patients  
316 with the *GSTA2*\*C/\*B haplotype (rs6577/rs2180314), and 2 patients with the homozygous *GSTA2*\*C/\*C  
317 haplotype (rs2180314/rs2180134). In unadjusted analysis, *GSTA2* genotype (*GSTA2*\*C/\*B or  
318 *GSTA2*\*C/\*C versus *GSTA2*\*B/\*B) was associated with urine oxidative DNA damage, as shown in  
319 Figure 5b ( $p=0.03$ ). In contrast, neither the *GSTP1* rs1695 variant, previously identified as a predictor of  
320 isoniazid toxicity in a Chinese cohort<sup>21</sup>, nor the *GSTM1* null variant were associated with urine oxidative  
321 DNA damage; however the number of patients with the *GSTM1* null variant was small ( $n=3$ ).  
322  
323 Next, we examined the relationship between isoniazid pharmacokinetic exposures and urine oxidative  
324 DNA damage in a multivariate linear regression model. Based on our *a priori* criteria for model inclusion  
325 (greater than 20% change in the regression coefficient when the confounder was included in the  
326 model), the final multiple linear regression model included the confounding effects of body weight and  
327 renal function on the association between isoniazid  $C_{max}$  and urine oxidative DNA damage (Table 3).  
328 Although not a significant confounder of this relationship, we included the effects of *GSTA2* genotype  
329 (\*B/\*B vs \*C/\*B or \*C/\*C) based on its independent association with urine levels of oxidative DNA  
330 damage in unadjusted analysis. The corresponding increase in adjusted R-squared with sequential  
331 variable inclusion, along with the decline in Akaike information criteria (AIC) score, provided statistical  
332 support for choosing model as variables were added. Variance inflation factors for the variables in the  
333 final model were 1.31, 2.38, 1.78, and 1.39 for isoniazid  $C_{max}$ , body weight, creatinine clearance, and

334 *GSTA2* genotype, respectively, supporting the absence of significant co-linearity among model  
335 predictors.

336

337 Figure 5c is a marginal regression plot of isoniazid  $C_{max}$  and urine oxidative DNA damage, with effect  
338 modification by *GSTA2* genotype. Although the graphical relationship suggests that *GSTA2* genotype  
339 acts both as an independent predictor as well as an effect modifier of the relationship between isoniazid  
340  $C_{max}$  and urine oxidative DNA damage, the difference in slopes did not reach the *a priori* threshold for  
341 statistical significance ( $p=0.12$  for interaction term).

342

## 343 **DISCUSSION**

344 Despite being a cornerstone of TB therapy for 60 years, there is considerable uncertainty regarding the  
345 mechanism for isoniazid hepatotoxicity, and the host factors that place TB patients at greatest risk. We  
346 first characterized plasma exposures to isoniazid and its metabolites (acetylisoniazid, hydrazine, and  
347 acetylhydrazine) in a clinical pharmacokinetic study, demonstrating that isoniazid and hydrazine plasma  
348 exposures are highly correlated. Based on these clinical data, we predicted liver tissue exposures using  
349 physiologically based pharmacokinetic modeling, observing that hydrazine concentrates in liver relative  
350 to plasma. We then developed a long-term, low-exposure experimental set-up in HepG2 cells in order  
351 to replicate parent-metabolite pharmacologic exposures in the liver during the course of isoniazid  
352 treatment. We found that the greatest levels of mitochondrial injury and oxidative DNA damage  
353 occurred with hydrazine treatment at equimolar concentrations. Finally, In a clinical translation of this  
354 observation, we observed that peak isoniazid serum concentrations and *GSTA2* genotype were  
355 independently associated with increasing urine levels of oxidative DNA damage.

356

357 These findings link pharmacokinetic exposures to hydrazine, an isoniazid metabolite, with downstream  
358 effects on redox imbalance, adding to prior clinical studies of predictors of isoniazid hepatotoxicity. Slow

359 acetylators of isoniazid, as defined by *NAT2* genotype, have an increased risk of hepatotoxicity  
360 compared to intermediate or rapid acetylators, possessing one or two rapid *NAT2* alleles,  
361 respectively<sup>27</sup>. In a prior clinical study, peak serum isoniazid concentrations were directly correlated  
362 with elevations in liver transaminases, a marker of hepatic inflammation<sup>28</sup>. Future work should identify  
363 whether early markers of oxidative stress among isoniazid-treated patients, such as the urine measure  
364 of DNA damage identified in this clinical study, are predictive of subsequent hepatotoxicity events. For  
365 example, a cross-sectional study among isoniazid-treated TB patients in India demonstrated an  
366 association between hepatotoxicity events and co-incident measurements of plasma oxidative stress  
367 markers<sup>12</sup>.

368

369 The *GSTA2* gene encodes a protein sub-unit of  $\alpha$ -GST, the predominant GST enzyme expressed in  
370 human liver tissue<sup>23</sup>. Previously published data demonstrated decreased  $\alpha$ -GST expression in liver  
371 tissue among individuals either heterozygous or homozygous for the *GSTA2*\*C allele, suggesting  
372 greater vulnerability to oxidative hepatic injury<sup>22</sup>. Consistent with this observation, we found that the  
373 *GSTA2*\*C haplotype, either heterozygous or homozygous, was an independent predictor of urine  
374 oxidative DNA damage among HIV/TB patients. In contrast, we observed no relationship between urine  
375 oxidative DNA damage and the rs1695 allele in *GSTP1*, previously linked to anti-TB drug toxicity  
376 among Chinese patients<sup>21</sup>, or the null mutant *GSTM1*.

377

378 The involvement of glutathione pathways in the development of isoniazid hepatotoxicity could identify  
379 both preventive and therapeutic strategies. Hydrazine cellular effects include inhibition of complex II of  
380 the electron transport chain, leading to accumulation of ROS that overwhelms cellular glutathione  
381 stores, and directly damaging to DNA through free radical injury<sup>29</sup>. N-acetylcysteine, clinically used to  
382 counter acetaminophen toxicity, has also been used for glutathione deficiency in a wide range of  
383 conditions<sup>30</sup>. Identification of intermediary signals on the pathway towards clinical hepatotoxicity events,



384 such as oxidative DNA damage, would also improve efficiency of future clinical trial design of novel TB  
385 drug therapies, as isoniazid may be included in these investigational drug combinations<sup>3</sup>.

386

387 Aside from hepatotoxicity, oxidative DNA damage during isoniazid treatment may have additional  
388 downstream consequences. DNA damage signals induce the nuclear activity of poly(ADP-ribose)  
389 polymerase-1 (PARP-1), which is involved in DNA repair activities through multiple pathways<sup>31</sup>. Chronic  
390 PARP-1 activation competes for intracellular NAD<sup>+</sup>, resulting in impaired mitochondrial ATP production  
391 and cellular apoptosis<sup>32</sup>. Thus, when considering the clinical implications of increased markers of  
392 oxidative DNA damage, additional effects aside from hepatotoxicity events should be considered. For  
393 example, isoniazid treatment has been linked to increased markers of cellular apoptosis in immune  
394 cells, and direct effects of isoniazid on the patient's immune-metabolism has been suggested.  
395 Intriguingly, isoniazid treatment in mice induced apoptosis markers in CD4<sup>+</sup> T cells<sup>33</sup>. Future clinical  
396 studies should directly compare isoniazid and metabolite pharmacokinetic exposures with  
397 toxicodynamic markers of redox imbalance, including urine markers of oxidative DNA damage.

398

399 This clinical and translational study of redox imbalance related to isoniazid and its metabolites had  
400 several important limitations. Rather than directly measure concentrations in liver tissue, we used  
401 physiologically based pharmacokinetic models to estimate liver tissue exposures for each compound. In  
402 the clinical validation study, the metabolite concentrations were not measured, and thus we cannot  
403 directly evaluate the relationship between metabolite exposures (such as hydrazine) and oxidative  
404 stress in this clinical cohort. Based on our pre-clinical observations, we hypothesize that hydrazine  
405 exposures, rather than isoniazid exposures, would demonstrate the greatest association with urine  
406 oxidative DNA damage among isoniazid-treated TB patients. Furthermore, we did not perform  
407 prospective serial monitoring of hepatic transaminases in the clinical cohort, and the significance of  
408 increased urine oxidative stress markers during isoniazid treatment remains uncertain. Prospective  
409 studies of oxidative stress markers, particularly the urine measure of oxidative DNA damage identified



410 in this study, will be essential to unravel the link between isoniazid and metabolite exposures,  
411 hepatocellular oxidative stress, and clinical hepatotoxicity events.

412

413 This study had several strengths. Unlike many earlier studies, we examined physiologically relevant  
414 isoniazid and metabolite concentrations, supported by a parent-metabolite clinical pharmacokinetic  
415 study and physiologically-based pharmacokinetic modeling<sup>34</sup>. We *in vitro* experiments to provide a  
416 mechanistic link between physiologic exposures to these compounds and cellular signals for redox  
417 imbalance and oxidative DNA damage. In this approach, we identified a marker of oxidative DNA  
418 damage, 8-OHdG, which was strongly induced by hydrazine exposures in the cell model, which we  
419 then related to isoniazid pharmacokinetic exposures and *GSTA2* genotype in a clinical study. The  
420 identification of a urine-based biomarker of oxidative stress related to pharmacokinetic exposures  
421 and/or patient genotype supports non-invasive sampling strategies in future prospective studies of  
422 isoniazid toxicity. The feasibility of this future work is enhanced by the potential for point-of-care  
423 detection of 8-OHdG in paper-based devices<sup>35</sup>.

424

425 In summary, the hydrazine metabolite of isoniazid was the strongest inducer of redox imbalance and  
426 downstream oxidative DNA damage in HepG2 cells over long-term exposures to clinically relevant  
427 concentrations. In a study of isoniazid-treated TB patients, peak serum isoniazid concentrations and  
428 *GSTA2* genotype were independently associated with urine levels of 8-OHdG, a marker of oxidative  
429 DNA damage. Future clinical studies should evaluate urine 8-OHdG as an early predictor of clinical  
430 hepatotoxicity during isoniazid treatment.

431

432 Funding: CV was supported by NIAID (K23AI102639, R01AI137080).

433 Ethics statement: The institutional review boards of the University of Pennsylvania, Botswana Ministry  
434 of Health, and the Princess Marina Hospital approved the clinical study. All participants provided written  
435 informed consent.

436

437 **FIGURE LEGENDS**

438 **Figure 1.** Metabolic pathway of isoniazid.

439 **Figure 2.** Plasma concentration-time exposures of isoniazid and its metabolites. Figure 2a. Isoniazid.

440 Figure 2b. Acetylisoniazid. Figure 2c. Hydrazine. Figure 2d. Acetylhydrazine. Figure 2e. Correlation of  
441 isoniazid and hydrazine AUC<sub>0-24</sub>.


442 **Figure 3.** Mitochondrial injury and glutathione depletion in HepG2 cells treated with isoniazid and  
443 metabolites over 28 days. Figure 3a. Cytotoxicity. Figure 3b. Free thiol assay. Figure 3c. Mitochondrial  
444 membrane integrity. Figure 3d. ATP production.

445 **Figure 4.** DNA damage markers in HepG2 cells treated with isoniazid and metabolites. Figure 4a.  
446 Comet chip microscopy of DNA damage after 7 days exposure. Figure 4b. Percentage of DNA in comet  
447 tail for isoniazid and metabolites after 7 days exposure. Figure 4c. Levels of phosphorylated gamma-  
448 p2Ax levels in HepG2 cells after 28 days exposure. Figure 4d. 8-OhDG levels in cellular supernatant  
449 following 28 days exposure.

450 **Figure 5.** Urine levels of oxidative DNA damage among HIV/TB patients, grouped by NAT2 and GSTA2  
451 genotypes. Figure 5a. NAT2 genotype and urine oxidative DNA damage. Figure 5b. GSTA2 genotype  
452 and urine oxidative DNA damage. Figure 5c. Margins plot of interaction between isoniazid C<sub>max</sub> and  
453 GSTA2 genotype. Each line represents marginal predicted levels of oxidative DNA damage for varying  
454 isoniazid C<sub>max</sub>, according to GSTA2 genotype, and the shaded areas represent 95% confidence  
455 intervals. Solid line: GSTA2 \*B/\*B; dashed line: GSTA2 \*C/\*B or \*C.

456 **Figure 1.** Metabolic pathway of isoniazid<sup>36</sup>. Reproduced with permission.

457



458

459 **Figure 2.** Plasma concentration-time exposures of isoniazid and its metabolites among 10 isoniazid-  
460 treated patients. Black line/triangles: active TB patients; grey line/circles: latent TB patients.

Figure 2a. Isoniazid.




Figure 2b. Acetylisoniazid.




Figure 2c. Hydrazine.





Figure 2d. Acetylhydrazine.



**Figure 3.** Redox imbalance and mitochondrial impairment in HepG2 cells treated with isoniazid and metabolites over 28 days.

Figure 3a. Overall cytotoxicity.




Figure 3b. Free thiol availability assay.




Figure 3c. Mitochondrial membrane integrity.





Figure 3d. ATP production.



**Figure 4.** DNA damage markers in HepG2 cells treated with isoniazid and metabolites.

Figure 4a. CometChip representative images after 1-week exposure.




Figure 4b. Percentage of DNA in comet tail for isoniazid and metabolites after 7 days exposure.






Figure 4c. Levels of phosphorylated  $\gamma$ -pH2Ax levels in HepG2 cells.





Figure 4d. 8-OHdG levels in cell supernatant.



**Figure 5.** Urine levels of oxidative DNA damage among isoniazid-treated HIV/TB patients.

Figure 5a. Univariate association with *NAT2* genotype ( $p=0.04$ ).




Figure 5b. Univariate association with *GSTA2* genotype ( $p=.03$ ).





Figure 5c. Margins plot of interaction between isoniazid  $C_{max}$  and *GSTA2* genotype in determining levels of urine oxidative DNA damage in the multivariate linear regression model.



**Table 1.** Predicted liver tissue exposures of isoniazid and metabolites.

<b>Compound</b>	<b>Observed median (range) of plasma AUC<sub>0-24</sub> (uM*hr)</b>	<b>Predicted ratio of liver/plasma AUC<sub>0-24</sub></b>	<b>Predicted median liver AUC<sub>0-24</sub> (uM*hr)</b>
Isoniazid	60.5 (28.4, 269.4)	0.72	43.6
Acetylisoniazid	157.6 (72.2, 349.8)	0.72	113.5
Hydrazine	14.5 (3.0, 27.8)	18.08	262.2
Acetylhydrazine	66.6 (43.2, 198.0)	0.79	52.6

**Table 2.** Characteristics of HIV/TB patients, stratified by *NAT2* genotype.


Characteristic	Slow <i>NAT2</i> genotype (N=7)	Intermediate <i>NAT2</i> genotype (N=20)	Rapid <i>NAT2</i> genotype (N=13)	P-value
Median age (years) (range)	30 (24 - 44)	32 (25 - 48)	32 (24 - 49)	0.54
Male sex (%)	2 (29%)	11 (55%)	9 (69%)	0.22
Median body weight (kg) (range)	55.0 (44.0 - 67.0)	54.8 (37.3 - 77.0)	55.0 (42 - 60.5)	0.64
Median creatinine clearance (mL/min) (range)	100.9 (85.3 - 129.6)	107.2 (68.4 - 141.3)	98.4 (40.1 - 157.6)	0.69
Number of current smokers (%)	0 (0%)	1 (5%)	2 (15%)	0.40
Number with positive AFB sputum smear (%)	4 (57%)	15 (79%)	9 (69%)	0.53
Median CD4+ T cell count (cells/mL <sup>3</sup> ) (range)	252 (208 - 486)	238 (36 - 501)	209 (11 - 735)	0.69
Median HIV viral load (copies/mL) (range)	2.5x10 <sup>4</sup> (1.6x10 <sup>3</sup> - 7.0x10 <sup>6</sup> )	1.1x10 <sup>5</sup> (86 - 5.1x10 <sup>6</sup> )	1.3x10 <sup>5</sup> (4.3x10 <sup>3</sup> - 1.8x10 <sup>6</sup> )	0.72

**Table 3.** Linear regression model of predictors of urine oxidative DNA damage among isoniazid-treated HIV/TB patients.

Characteristic	Unadjusted regression coefficient (95% CI)	P-value	Adjusted regression coefficient (95% CI)	P-value
Age (years)	-0.013 (-0.067, 0.041)	0.63		
Sex		0.36		
Male (n=)	Reference			
Female (n=)	0.391 (-0.464, 1.247)			
Body weight (kg)	-0.004 (-0.055, 0.047)	0.88	-0.094 (-0.164, -0.026)	0.01
Creatinine clearance (mL/hr)	0.010 (-0.011, 0.031)	0.35	0.020 (-0.005, 0.045)	0.11
Positive AFB sputum smear	-0.449 (-1.396, 0.498)	0.34		
Days of TB treatment	0.004 (-0.029, 0.038)	0.80		
CD4+ T cell count (cells/mL <sup>3</sup> )	0.001 (-0.002, 0.003)	0.48		
Log HIV viral load	-0.009 (-0.193, 0.175)	0.92		
CRP	0.014 (-0.012, 0.040)	0.28		
Log IL-6	-0.001 (-0.009, 0.008)	0.85		
<b>Isoniazid pharmacokinetic exposures</b>				
Isoniazid C <sub>max</sub> (mg/L)	0.153 (-0.060, 0.366)	0.15	0.241 (0.020, 0.462)	0.03
Isoniazid log AUC <sub>0-24</sub>	0.474 (-0.272, 1.221)	0.21		
<b>Pharmacogenetic variability</b>				
NAT2 genotype		0.12		
Rapid (n=13)	Reference			
Intermediate (n=20)	0.616 (-0.311, 1.544)			
Slow (n=7)	1.241 (0.033, 2.449)			

<i>GSTA2</i> genotype				
<i>GSTA2</i> *B/*B (n=25)	Reference			
<i>GSTA2</i> *B/*C (n=12) or <i>GSTA2</i> *C/*C (n=2)	0.971 (0.131, 1.810)	0.03	1.259 (0.321, 2.198)	0.02
<i>GSTP1</i> SNP rs1695		0.34		
WT/WT (n=5)	Reference			
WT/Var (n=26)	0.848 (-0.359, 2.054)			
Var/Var (n=8)	0.469 (-0.965, 1.902)			
<i>GSTM1</i> null genotype (n=3)	-0.819 (-2.415, 0.777)	0.31		

**Supplementary Figure 1.** Physiologically-based pharmacokinetic model of isoniazid and metabolites.





**Supplementary Table 1.** Parameters used in the physiologically-based pharmacokinetic model of isoniazid and metabolites.

Tissue Compartment	Volume (L)	Simulated $K_p$			
		Isoniazid	Acetylisoniazid	Hydrazine	Acetylhydrazine
Lung	1.14	0.72	0.70	14.31	0.79
Arterial supply	2.11	0	0	0.00	0.00
Venous return	4.22	0	0	0.00	0.00
Adipose	21.00	0.17	0.17	1.55	0.18
Muscle	23.96	0.66	0.64	6.48	0.73
Liver	1.53	0.67	0.65	16.54	0.74
Spleen	0.17	0.70	0.67	11.96	0.77
Heart	0.33	0.71	0.69	8.71	0.78
Brain	1.49	0.70	0.69	2.68	0.77
Kidney	0.35	0.70	0.67	18.06	0.76
Skin	2.73	0.66	0.65	5.43	0.71
Reproductive organs	0.05	0.70	0.68	18.06	0.77
Red marrow	1.07	0.41	0.41	3.00	0.43
Yellow marrow	2.97	0.17	0.17	1.55	0.18
Rest of body	2.50	0.70	0.68	11.96	0.77

**Supplementary Table 2.** Properties of HPLC-MS/MS plasma assays for isoniazid and metabolites.

<b>Analyte</b>	<b>Lower limit of quantification (LLOQ, ng/mL)</b>	<b>Limit of detection (LOD, ng/mL)</b>	<b>Inter-day variability (% Bias)</b>	<b>Intra-day variability (% Bias)</b>
Isoniazid	1	0.8	3.0	-1.6
Acetylisoniazid	10	6.4	2.0	2.1
Hydrazine	2	0.4	-3.0	-8.5
Acetylhydrazine	10	2.0	-3.5	-3.4

**Supplementary Table 3.** GSTA2 haplotype designations based on SNPs, according to naming schema proposed by Tetlow *et al.* The rs2234951 and rs1803682 variants were not detected in the patient cohort; rs6577 and rs2180314 were in complete linkage disequilibrium.

<b>GSTA2 haplotype</b>	<b>rs2234951 (P110S)</b>	<b>rs2180314 (S112T)</b>	<b>rs1803682 (K196N)</b>	<b>rs6577 (A210C)</b>
GSTA2*A	-	-	-	-
GSTA2*B	-	-	-	+
GSTA2*C	-	+	-	-
GSTA2*D	-	-	+	-
GSTA2*E	+	-	-	-

## REFERENCES

1. Hayashi PH, Fontana RJ, Chalasani NP, et al. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. *Clin Gastroenterol Hepatol* 2015;13:1676-82 e1.
2. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 2006;174:935-52.
3. Wallis RS. Sustainable tuberculosis drug development. *Clin Infect Dis* 2013;56:106-13.
4. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. *Am J Respir Crit Care Med* 1998;157:1871-6.
5. Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini-review. *J Appl Toxicol* 2015;35:1427-32.
6. Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biol* 2015;4:180-3.
7. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. *Mol Interv* 2010;10:98-111.
8. Roth AD, Lee MY. Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays. *Biomed Res Int* 2017;2017:9176937.
9. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu Rev Pharmacol Toxicol* 2005;45:51-88.
10. Friedman JR, Nunnari J. Mitochondrial form and function. *Nature* 2014;505:335-43.
11. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. *Br J Clin Pharmacol* 2016;81:1030-6.
12. Chowdhury A, Santra A, Kundu S, et al. Induction of oxidative stress in antitubercular drug-induced hepatotoxicity. *Indian J Gastroenterol* 2001;20:97-100.
13. Yew WW, Chang KC, Chan DP. Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. *Antimicrob Agents Chemother* 2018;62.

14. Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. *Cell Biol Toxicol* 2012;28:69-87.
15. Tomanek L. Proteomic responses to environmentally induced oxidative stress. *J Exp Biol* 2015;218:1867-79.
16. Mandavilli BS, Janes MS. Detection of intracellular glutathione using ThiolTracker violet stain and fluorescence microscopy. *Curr Protoc Cytom* 2010;Chapter 9:Unit 9 35.
17. Ge J, Prasongtanakij S, Wood DK, et al. CometChip: a high-throughput 96-well platform for measuring DNA damage in microarrayed human cells. *J Vis Exp* 2014:e50607.
18. Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S. DNA damage foci: Meaning and significance. *Environ Mol Mutagen* 2015;56:491-504.
19. Vinnard C, Ravimohan S, Tamuhla N, et al. Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. *Br J Clin Pharmacol* 2017;83:801-11.
20. Doll MA, Hein DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. *Anal Biochem* 2001;288:106-8.
21. Wu S, Wang YJ, Tang X, et al. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. *PLoS One* 2016;11:e0157478.
22. Ning B, Wang C, Morel F, et al. Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. *Pharmacogenetics* 2004;14:35-44.
23. Tetlow N, Liu D, Board P. Polymorphism of human Alpha class glutathione transferases. *Pharmacogenetics* 2001;11:609-17.

24. Frijhoff J, Winyard PG, Zarkovic N, et al. Clinical Relevance of Biomarkers of Oxidative Stress. *Antioxid Redox Signal* 2015;23:1144-70.
25. Pizzino G, Bitto A, Interdonato M, et al. Oxidative stress and DNA repair and detoxification gene expression in adolescents exposed to heavy metals living in the Milazzo-Valle del Mela area (Sicily, Italy). *Redox Biol* 2014;2:686-93.
26. Pawlas N, Olewinska E, Markiewicz-Gorka I, et al. Oxidative damage of DNA in subjects occupationally exposed to lead. *Adv Clin Exp Med* 2017;26:939-45.
27. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. *Int J Tuberc Lung Dis* 2012;16:589-95.
28. Cojutti P, Duranti S, Isola M, et al. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? *J Antimicrob Chemother* 2016;71:1323-9.
29. Runge-Morris M, Wu N, Novak RF. Hydrazine-mediated DNA damage: role of hemoprotein, electron transport, and organic free radicals. *Toxicol Appl Pharmacol* 1994;125:123-32.
30. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 2007;7:355-9.
31. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. *Mol Cell* 2010;39:8-24.
32. Fang EF, Scheibye-Knudsen M, Brace LE, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. *Cell* 2014;157:882-96.
33. Tousif S, Singh DK, Ahmad S, et al. Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection. *J Biol Chem* 2014;289:30190-5.
34. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. *Drug Metab Dispos* 2015;43:1823-37.

35. Martins GV, Tavares APM, Fortunato E, Sales MGF. Paper-Based Sensing Device for Electrochemical Detection of Oxidative Stress Biomarker 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in Point-of-Care. *Sci Rep* 2017;7:14558.

36. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. *In Vivo* 2011;25:803-12.